Literature DB >> 12003637

Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancer.

Andrew M Woods1, Who W Wang, David M Shaw, Christopher M Ward, Miles W Carroll, Buddug R Rees, Peter L Stern.   

Abstract

Human 5T4 oncofoetal antigen defined by the murine 5T4 monoclonal antibody is a highly glycosylated protein expressed by trophoblast and a few specialized adult epithelia. Up-regulation of 5T4 expression in some cancers is associated with poor clinical outcome; overexpression of human 5T4 cDNA in epithelial cells can alter their morphology and motility, supporting a role for such functions in cancer and development. A murine model to study 5T4 biology and tumour immunology would be useful. The production of m5T4-specific antibodies, their use in establishing transfected cells and documenting their biological properties in vitro are described. A rat monoclonal antibody specific for mouse 5T4 molecules by ELISA, flow cytometry, immunohistochemistry and immunoprecipitation was isolated and epitope mapped. Similar to its human counterpart, murine 5T4 antigen is a 72 kDa glycoprotein (immunoprecipitation and Western blot analysis) and exhibits punctate cell surface expression, dependent upon the integrity of the actin cytoskeleton. Likewise, overexpression of autologous murine 5T4 by B16 F10 melanoma cells and A9 L fibroblasts accentuates the 5T4 phenotype, which is characterized by a spindle-like morphology, increased motility, and reduced adhesion and proliferation rate. Immunohistochemical analysis of adult mouse tissues shows a restricted pattern of expression similar to that of human 5T4 antigen. The murine 5T4 antigen-expressing cell lines and antibody reagents are now being used to explore novel immunotherapies in pre-clinical models and the biology of 5T4 in development.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12003637      PMCID: PMC1222756          DOI: 10.1042/BJ20020104

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  28 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 2.  Cell volume and the metabolic actions of insulin.

Authors:  R Zhande; R W Brownsey
Journal:  Biochem Cell Biol       Date:  1996       Impact factor: 3.626

3.  Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells.

Authors:  C J Carsberg; K A Myers; P L Stern
Journal:  Int J Cancer       Date:  1996-09-27       Impact factor: 7.396

4.  The acid-labile subunit of the serum insulin-like growth factor-binding protein complexes. Structural determination by molecular modeling and electron microscopy.

Authors:  J B Janosi; P A Ramsland; M R Mott; S M Firth; R C Baxter; P J Delhanty
Journal:  J Biol Chem       Date:  1999-08-13       Impact factor: 5.157

5.  5T4 oncofetal antigen expression in ovarian carcinoma.

Authors:  E. Wrigley; A.T. McGown; J. Rennison; R. Swindell; D. Crowther; T. Starzynska; P.L. Stern
Journal:  Int J Gynecol Cancer       Date:  1995-07       Impact factor: 3.437

6.  Cell hydration and insulin signalling.

Authors:  F Schliess; D Häussinger
Journal:  Cell Physiol Biochem       Date:  2000

7.  5T4 oncofetal antigen in gastric carcinoma and its clinical significance.

Authors:  T Starzynska; A Wiechowska-Kozlowska; K Marlicz; M Bromley; S A Roberts; M Lawniczak; B Kolodziej; A Zyluk; P L Stern
Journal:  Eur J Gastroenterol Hepatol       Date:  1998-06       Impact factor: 2.566

8.  Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine.

Authors:  V Bronte; M W Carroll; T J Goletz; M Wang; W W Overwijk; F Marincola; S A Rosenberg; B Moss; N P Restifo
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

9.  Immunohistological distribution of 5T4 antigen in normal and malignant tissues.

Authors:  P J Southall; G M Boxer; K D Bagshawe; N Hole; M Bromley; P L Stern
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

10.  Metastasis-associated 5T4 oncofoetal antigen is concentrated at microvillus projections of the plasma membrane.

Authors:  C J Carsberg; K A Myers; G S Evans; T D Allen; P L Stern
Journal:  J Cell Sci       Date:  1995-08       Impact factor: 5.285

View more
  7 in total

1.  CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells.

Authors:  Thomas D Southgate; Owen J McGinn; Fernanda V Castro; Andrzej J Rutkowski; Mariam Al-Muftah; Georgi Marinov; Graeme J Smethurst; David Shaw; Christopher M Ward; Crispin J Miller; Peter L Stern
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

2.  CD59 blockade enhances antigen-specific CD4+ T cell responses in humans: a new target for cancer immunotherapy?

Authors:  Baalasubramanian Sivasankar; M Paula Longhi; Kathleen M E Gallagher; Gareth J Betts; B Paul Morgan; Andrew J Godkin; Awen M Gallimore
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

3.  E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cells.

Authors:  Helen L Spencer; Angela M Eastham; Catherine L R Merry; Thomas D Southgate; Flor Perez-Campo; Francesca Soncin; Sarah Ritson; Rolf Kemler; Peter L Stern; Christopher M Ward
Journal:  Mol Biol Cell       Date:  2007-05-16       Impact factor: 4.138

4.  5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy.

Authors:  Federica Cappuccini; Emily Pollock; Stephen Stribbling; Adrian V S Hill; Irina Redchenko
Journal:  Oncotarget       Date:  2017-07-18

5.  Novel tri-specific tribodies induce strong T cell activation and anti-tumor effects in vitro and in vivo.

Authors:  Margherita Passariello; Asami Yoshioka; Kota Takahashi; Shu-Ichi Hashimoto; Toshikazu Inoue; Koji Nakamura; Claudia De Lorenzo
Journal:  J Exp Clin Cancer Res       Date:  2022-09-07

6.  Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.

Authors:  Howard L Kaufman; Bret Taback; William Sherman; Dae Won Kim; William H Shingler; Dorota Moroziewicz; Gail DeRaffele; Josephine Mitcham; Miles W Carroll; Richard Harrop; Stuart Naylor; Seunghee Kim-Schulze
Journal:  J Transl Med       Date:  2009-01-07       Impact factor: 5.531

7.  Structural insights into the inhibition of Wnt signaling by cancer antigen 5T4/Wnt-activated inhibitory factor 1.

Authors:  Yuguang Zhao; Tomas Malinauskas; Karl Harlos; E Yvonne Jones
Journal:  Structure       Date:  2014-02-27       Impact factor: 5.006

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.